immunocore.com (IMCR): Price-to-Projected Revenue Ratio

IMCR (Immunocore Holdings) - company brandmark

Immunocore Holdings plc utilizes a unique TCR platform to combat solid tumors and ocular melanoma. The GURU.Markets terminal displays the company's expected P/S chart, where the value 3.30 represents the current metric. This British breakthrough in oncology has secured physician trust for the brand. Leadership in treating rare cancers guarantees high margins and strong pricing power.

IMCR Immunocore Holdings: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/18/2026

Analytical breakdowns for Immunocore Holdings plc (IMCR)

- stock exchange capitalization data:
Summary company analysis:immunocore.com IMCR
Manufactured products of Immunocore Corp

Immunocore Holdings plc (IMCR) is transitioning to the commercial scaling stage, leveraging operating leverage to optimize research costs. The current calculated coefficient 3.30 reflects the ratio of market capitalization to projected annual revenue, measuring the premium for future growth. Investors utilize this metric to assess whether the asset is overbought relative to expected cash flows. The trend of the company's expected P/S on the GURU.Markets platform allows for the real-time assessment of shifting market sentiment.

Competitor analysis

ImmunityBio Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Janux Corp JANX|RCUS - Price-to-Projected Revenue Ratio|ZYME (zymeworks.com) - Market Cap to Projected Revenue|Tango Therapeutics Corp (TNGX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Iovance (IOVA)|Forward Price-to-Revenue Multiple IMTX|XNCR - Projected Price to Revenue|Forward Price-to-Revenue Multiple CMPX (Compass Bio)|Price to Expected Revenue Ratio REPL|Forward P/S Multiple LYEL (Lyell Immunopharma, Inc.)|Forward Price to Sales IPHA|Pyxis - Forward P/S Multiple|Market Cap to Future Revenue Ratio Compugen|IO Biotech, Inc. (IOBT) - Price-to-Projected Revenue Ratio|Sutro Biopharma, Inc. - Forward Price to Sales|INKT (minktherapeutics.com) - Forward P/S Multiple|Forward P/S Multiple werewolftx.com|Price-to-Projected Revenue Ratio immixbio.com (IMMX)|ALXO: Future Price to Revenue|Forward P/S Multiple CUE (Cue Biopharma Inc.)|PDS Biotechnology (PDSB) - Market Cap to Future Revenue Ratio|SONN - Price-to-Projected Revenue Ratio|MAIA Biotechnology, Inc. (MAIA) - Forward Price-to-Revenue Multiple|LIMN: Forward P/S Multiple|LAVA Therapeutics N.V. (LVTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple NXTC|Forward P/S Multiple leaptx.com|Forward P/S Multiple INTS|Market Cap to Expected Sales Ratio Sensei Biotherapeutics, Inc.|Forward P/S Multiple TOVX (Theriva Corp)|Market Cap to Expected Sales Ratio gritstonebio.com (GRTS)|kinetabio.com - Forward P/S Multiple|NexImmune (NEXI) - Forward Price-to-Revenue Multiple|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vaccinex, Inc (VCNX)|Forward Price-to-Revenue Multiple HARP